FY13 Priorities. Avant-Garde (DP1) A- START (R03/$100K) IAS /NIDA Fellowship ($75K) Advancing exceptional HIV /AIDS Research (R01/RFA) Technology-Base Adherence Research (PA) NIDA Drug Abuse and HIV Cohorts (PAR/U01) Provide supplements for NIAID’s ACTG
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Jeremy Luban, M.D.
University of Massachusetts, Medical School, Worcester
David Smith, M.D.
University of California, San Diego School of Medicine
Samuel Friedman, Ph.D.
National Development and Research Institutes, New York City
Molecular epidemiology for HIV prevention for drug users and other risk groups
Preventing HIV transmission by recently-infected drug users
Human genes that influence HIV-1 replication, pathogenesis, and immunity in intravenous drug users